Patents by Inventor Meher Majety

Meher Majety has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTI-CCL2 ANTIBODIES
    Publication number: 20240117029
    Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
    Type: Application
    Filed: November 14, 2023
    Publication date: April 11, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jens FISCHER, Guy GEORGES, Anton JOCHNER, Gregor JORDAN, Hubert KETTENBERGER, Joerg MOELLEKEN, Tilman SCHLOTHAUER, Georg TIEFENTHALER, Valeria RUNZA, Meher MAJETY, Martin SCHAEFER, Maria VIERT, Shu FENG, Wei Shiong Adrian HO, Siok Wan GAN, Runyi Adeline LAM, Michael GERTZ
  • BISPECIFIC ANTI-CCL2 ANTIBODIES
    Publication number: 20240083993
    Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
    Type: Application
    Filed: June 15, 2023
    Publication date: March 14, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jens FISCHER, Guy GEORGES, Anton JOCHNER, Gregor JORDAN, Hubert KETTENBERGER, Joerg MOELLEKEN, Tilman SCHLOTHAUER, Georg TIEFENTHALER, Valeria RUNZA, Meher MAJETY, Martin SCHAEFER, Maria VIERT, Shu FENG, Wei Shiong Adrian HO, Siok Wan GAN, Runyi Adeline LAM, Michael GERTZ
  • Bispecific anti-CCL2 antibodies
    Patent number: 11739142
    Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: August 29, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jens Fischer, Guy Georges, Anton Jochner, Gregor Jordan, Hubert Kettenberger, Joerg Moelleken, Tilman Schlothauer, Georg Tiefenthaler, Valeria Runza, Meher Majety, Martin Schaefer, Maria Viert, Shu Feng, Wei Shiong Adrian Ho, Siok Wan Gan, Runyi Adeline Lam, Michael Gertz
  • ANTI-HLA-G ANTIBODIES AND USE THEREOF
    Publication number: 20230159642
    Abstract: The present invention relates to antibodies that bind to human HLA-G, multispecific antibodies thereof, their preparation, formulations, and methods of using the same.
    Type: Application
    Filed: October 18, 2022
    Publication date: May 25, 2023
    Inventors: Alexander BUJOTZEK, Alejandro CARPY GUTIERREZ CIRLOS, Anne FREIMOSER-GRUNDSCHOBER, Carina HAGE, Thomas HOFER, Silke KIRCHNER, Meher MAJETY, Ekkehard MOESSNER, Christiane NEUMANN, Christian SPICK, Georg TIEFENTHALER, Thomas WEINDL
  • Anti-HLA-G antibodies and use thereof
    Publication number: 20220213199
    Abstract: The present invention relates antibodies that bind to human HLA-G, multispecific antibodies thereof, their preparation, formulations and methods of using the same.
    Type: Application
    Filed: December 15, 2021
    Publication date: July 7, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Alexander Bujotzek, Alejandro Carpy Gutierrez Cirlos, Anne Freimoser-Grundschober, Carina Hage, Thomas Hofer, Silke Kirchner, Meher Majety, Ekkehard Moessner, Christiane Neumann, Christian Spick, Georg Tiefenthaler, Thomas Weindl
  • BISPECIFIC ANTI-CCL2 ANTIBODIES
    Publication number: 20210188960
    Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
    Type: Application
    Filed: December 16, 2020
    Publication date: June 24, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jens FISCHER, Guy GEORGES, Anton JOCHNER, Gregor JORDAN, Hubert KETTENBERGER, Joerg MOELLEKEN, Tilman SCHLOTHAUER, Georg TIEFENTHALER, Valeria RUNZA, Meher MAJETY, Martin SCHAEFER, Maria VIERT, Shu FENG, Wei Shiong Adrian HO, Siok Wan GAN, Runyi Adeline LAM, Michael GERTZ
  • ANTI-HLA-G ANTIBODIES AND USE THEREOF
    Publication number: 20210147553
    Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 20, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Sebastian FENN, Jens FISCHER, Andreas HINZ, Claudia KIRSTENPFAD, Stefan KLOSTERMANN, Joerg MOELLEKEN, Georg TIEFENTHALER, Sabine HOVES, Alexander BUJOTZEK, Meher MAJETY
  • MULTISPECIFIC ANTIBODIES AND USE THEREOF
    Publication number: 20210147554
    Abstract: The present invention relates to multispecific antibodies that bind to HLA-G ant to a T cell activating antigen, their preparation, formulations and methods of using the same.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 20, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Sebastian FENN, Jens FISCHER, Claudia KIRSTENPFAD, Stefan KLOSTERMANN, Joerg MOELLEKEN, Georg TIEFENTHALER, Alexander BUJOTZEK, Meher MAJETY, Silke KIRCHNER
  • ANTI-HLA-G ANTIBODIES AND USE THEREOF
    Publication number: 20200102389
    Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.
    Type: Application
    Filed: May 17, 2019
    Publication date: April 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jens FISCHER, Meher MAJETY, Stefan DENGL, Georg TIEFENTHALER, Stefan KLOSTERMANN, Claudia KIRSTENPFAD, Esther KOENIGSBERGER, Francesca ROS
  • COMBINATION THERAPY OF BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5 AND CHEMOTHERAPEUTIC AGENTS
    Publication number: 20180064808
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, and in particular to combination therapies employing such bispecific antibodies and a chemotherapeutic agent, and their use of these combination therapies for the treatment of cancer.
    Type: Application
    Filed: April 7, 2017
    Publication date: March 8, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas Friess, Oliver Krieter, Meher Majety, Katharina Wartha